ALCLS Cellectis

Etude de l'AG du 26/06/2017

Cette année encore, la société se distingue par le manque de transparence dans sa communication. En effet, au jour de rédaction de cette étude (14 jours avant l'Assemblée Générale), la société n'a pas transmis l'ensemble des documents nécéssaires à la prise de décision éclairée des actionnaires.

Ce manque de transparence conduit Proxinvest à recommander aux actionnaires de s'opposer à une très grande majorité des résolutions proposées lors de l'Assemblée Générale.

Proxinvest regrette par ailleurs que la société maintienne la possibilité de l'usage de ces autorisations financières en période d'offre publique, en raison de leur possible utilisation comme arme anti-OPA. Proxinvest considère en effet que les OPA sont des opportunités d'enrichissement pour les actionnaires et que la mise en place de tels outils n'est pas favorable à leurs intérêts.

13/06/2017
24 pages
FR

Research Provider

Founded in 1995, Proxinvest is an independent proxy firm supporting the engagement and proxy analysis processes of investors. Proxinvest mission is to analyse corporate governance practices and resolutions proposed at general meetings of listed firms.

Proxinvest main services are :

  • ​Proxy reports
  • Definition and monitoring of client customized voting guidelines
  • Corporate Governance Data and Rating
  • Thematic research
  • Engagement support

Proxinvest has been a pioneer and champion of good corporate governance and has grown into a recognised expert in the field.

Proxinvest is independently-owned and only works for investors : Proxinvest does not provide consulting services to the companies it covers, mitigating related risks to its clients and ensuring the independence of our analysis. As a result Proxinvest is able to take a robust, independent, engaged and unconflicted view of the companies in which our clients invest.

As Managing Partner of Expert Corprate Governance Service Ltd (ECGS), Proxinvest has built a large network of corporate governance experts to support clients in corporate governance analysis worldwide. 

Read more

Underlying

Health Care - France

Cellectis is a gene-editing company employing its core proprietary technologies to develop products in the field of immuno-oncology. UCART19 is Co.'s lead product. UCART19 is an engineered T-cell product which drives its ability to target and kill CD19-bearing cells, such as B-cell malignancies. Co. is also developing wholly-owned product candidates UCART123, UCARTCS1 and UCART38, which are in various stages of development. UCART 123, UCARTCS1 and UCART38 are engineered T-cell products that bear CARs that seek to kill cells expressing targets CD123, CS1 and CD38, respectively, which are found in other hematologic tumors, such as acute myeloid leukemia, or AML, and multiple myeloma, or MM.

Read more

ResearchPool Subscriptions

Get the most out of your insights

Get in touch